PISCES III : A CLINICAL RESEARCH STUDY OF STEM CELLS FOR PATIENTS WITH ONGOING DISABILITY AFTER STROKE

**Right now this phase of the trial only accepts patients that have had a stroke in the last 6-12 months.

Click here for information on how to apply for the study.

Current Studies

  • Myasthenia Gravis
    • Ravulizumab (Complement inhibitor)
    • Zilucoplan (Complement inhibitor)
    • Rozanolixizumab (FCRN inhibitor)
    • M281 (Momenta) (FCRN inhibitor)
    • LRP4/Agrin Study
  • CIDP
    • Rozanolixizumab (FCRN inhibitor)
    • Unilateral L5-S1 Radiculopathy
      • Rho Study SI 6603
  • Study involving patients on eculizumab having MG